LP
CRVS icon

LMR Partners’s Corvus Pharmaceuticals CRVS Stock Holding History

LMR Partners’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-29,858
Closed -$94.9K – 1430
2025
Q1 		$94.9K Buy
+29,858
New +$141K ﹤0.01% 1145
2023
Q2 		– Sell
-30,000
Closed -$27.3K – 940
2023
Q1 		$27.3K Hold
30,000
– – ﹤0.01% 987
2022
Q4 		$25.5K Hold
30,000
– – ﹤0.01% 1072
2022
Q3 		$25K Hold
30,000
– – ﹤0.01% 1146
2022
Q2 		$30K Hold
30,000
– – ﹤0.01% 1205
2022
Q1 		$49K Hold
30,000
– – ﹤0.01% 1195
2021
Q4 		$72K Hold
30,000
– – ﹤0.01% 1121
2021
Q3 		$145K Buy
+30,000
New +$88.8K ﹤0.01% 947

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LMR Partners's CRVS Position: Q2 2025 in Review

LMR Partners sold out of Corvus Pharmaceuticals (CRVS) in Q2 2025, closing a stake of 29,858 shares — an estimated $94.9K sold.

LMR Partners first reported a position in CRVS in Q3 2021 and held it in 8 quarters. The position peaked at $145K in Q3 2021. 92 funds tracked by Wall St. Rank hold CRVS as of Q2 2025.

  • LMR Partners reported no remaining Corvus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • LMR Partners sold 29,858 Corvus Pharmaceuticals shares in Q2 2025, an estimated $94.9K.
  • LMR Partners first reported a position in Corvus Pharmaceuticals in Q3 2021 and held it in 8 quarters.
  • LMR Partners's Corvus Pharmaceuticals position peaked at $145K in Q3 2021.
  • 92 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2025.

Based on LMR Partners's 13F filing for Q2 2025, filed 14 Aug 2025.